WuXi AppTec Co., Ltd. (2359.HK)
| Previous Close | 37.950 |
| Open | 37.800 |
| Bid | 37.250 x 0 |
| Ask | 37.300 x 0 |
| Day's Range | 37.150 - 38.200 |
| 52 Week Range | 32.600 - 103.600 |
| Volume | |
| Avg. Volume | 9,126,034 |
| Market Cap | 137.891B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 10.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.99 (2.61%) |
| Ex-Dividend Date | Jun 05, 2023 |
| 1y Target Est | N/A |
- PR Newswire
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 ("Reporting Period"):
- PR Newswire
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 ("Reporting Period"):
- PR Newswire
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
